首页> 外文期刊>Military Medicine: Official Journal of AMSUS, The Society of the Federal Health Agencies >An Evidence-Based Review of Epinephrine Administered via the Intraosseous Route in Animal Models of Cardiac Arrest
【24h】

An Evidence-Based Review of Epinephrine Administered via the Intraosseous Route in Animal Models of Cardiac Arrest

机译:在心脏骤停动物模型中通过骨内途径给予肾上腺素的循证研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: Intraosseous (10) access, enabling the rapid administration of epinephrine during cardiac arrest (CA), is crucial in promoting optimal postresuscitation outcomes in patients with poor vascular access. There is a question whether IO-administered epinephrine is equivalent to intravenously administered epinephrine during CA. Methods: The question guiding this evidence-based review was as follows: in adults suffering CA given epinephrine via the IO route, what is the resulting serum concentration of the drug compared to when administered intravenously? A search was conducted and the evidence appraised and leveled. Results: Four animal studies met the inclusion criteria. The sources showed no definitive evidence supporting equivalence between intravenous and IO epinephrine administered during CA. Intravenously administered epinephrine provides increased and faster appearing serum concentrations than IO-administered epinephrine. Evidence indicated epinephrine given via the sternal 10 route more closely approaches equivalence with intravenously administered epinephrine than when administered by the tibial 10 route. Conclusions: The clinician should consider using proximal 10 infusion sites such as the sternum or humerus when administering advanced cardiac life support drugs to rapidly achieve maximal therapeutic concentrations. Further studies are needed to determine the differences seen when epinephrine is administered by these routes during CA.
机译:目标:骨内(10)通路可在心搏停止(CA)期间快速给予肾上腺素,对于促进血管通路不良患者的最佳复苏后结果至关重要。有一个问题是,在CA期间,IO给药的肾上腺素是否等同于静脉内给药的肾上腺素。方法:指导以证据为基础的审查的问题如下:在通过IO途径给予肾上腺素的CA成年人中,与静脉内给药相比,该药物产生的血清浓度是多少?进行了搜索,并对证据进行了评估和整理。结果:四项动物研究符合纳入标准。资料显示,没有确切的证据支持在CA期间静脉注射和IO肾上腺素等效。静脉内给药的肾上腺素比IO给药的肾上腺素能增加和更快地出现血清浓度。有证据表明,通过胸骨10途径给予的肾上腺素比通过胫骨10途径给予的肾上腺素更接近于静脉注射肾上腺素。结论:临床医生在服用先进的心脏生命支持药物以迅速达到最大治疗浓度时应考虑使用近端10个输注部位,例如胸骨或肱骨。需要进一步的研究以确定在CA期间通过这些途径给予肾上腺素时所见的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号